Company intelligence / Profile preview
Recludix Pharma
San Diego, California, United Statesrecludixpharma.com ↗
- Ownership
- Private
- Employees
- ~55
- Development stage
- Other
01
Overview
Recludix has demonstrated preclinical proof-of-concept for its oral small molecule inhibitors targeting the SH2 domains of STAT6 and STAT3. The lead program REX‑8756 (STAT6 inhibitor) shows high potency/selectivity in biochemical/cellular assays and efficacy in murine asthma models. REX‑7117 (STAT3 inhibitor) has shown strong efficacy in vivo versus JAK/TYK2 inhibition for inflammatory arthritis models. No human clinical data reported as of May 2025.
- Therapeutic areas
- GastroenterologyPulmonologyImmunologyDermatologyNeurology
- Modalities
- Small molecules (oral inhibitors)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Sanofi – strategic collaboration on development/commercialization of oral STAT6 inhibitors with option for U.S. profit-sharing/co-promotion arrangement.
Beyond the preview
Go deeper on Recludix Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recludix Pharma.